date:Mar 21, 2013
akeup, he said.
For Complete Genomics, which went public in November 2010 but failed to turn a profit, the deal is reinvigorating. In June, the company announced it had hired a financial adviser to explore strategic options, including a possible sale, and said it would slash 55 jobs, about 20 percent of its work force.
The acquisition also continues a surge in Chinese investment in the US that reached a record $6.5 billion in 2012.
That BGI-Shenzhen prevailed in its takeover bid was all the m